Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis

Bartoli, Francesco; Crocamo, Cristina; Clerici, Massimo; Carrà, Giuseppe

doi:10.1016/j.euroneuro.2015.06.011

Cited by 51 publications

(19 citation statements)

References 55 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, Wampers et al (2012) reported differential effects of olanzapine and risperidone on adiponectin levels, in that adiponectin levels were increased over time in the risperidone-treated patients. In a meta-analysis, clozapine and olanzapine, but not quetiapine, were associated with lower levels of adiponectin as compared with risperidone (Bartoli et al 2015). In one previous study, aripiprazole was not associated with decreased adiponectin levels (Paredes et al 2014); however, data on antipsychotics other than clozapine and olanzapine are scarce.…”

Section: Discussionmentioning

confidence: 96%

“…There have been reports on the associations between plasma adipokines and metabolic parameters including body mass index (BMI) in patients with antipsychotics (Baptista and Beaulieu 2002;Hanssens et al 2008;Henderson et al 2015;Jin et al 2008). It has been postulated that adiponectin levels might relate to mechanisms of weight gain and other metabolic dysregulations induced by antipsychotics (Bartoli et al 2015). Although there have been reports on the relevance of adipokines for the metabolic effects of antipsychotics (Hosojima et al 2006;Murashita et al 2007;Murashita et al 2005;Richards et al 2006;Sporn et al 2005;Togo et al 2004), the comprehensive understanding of body weight gain and dysfunctional adiposity due to the administration of antipsychotics still remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study

Kim

Park

et al. 2017

Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study

Kim

Park

et al. 2017

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…While antipsychotics are the current standard pharmacological treatment for severe mental illnesses, as a class they are associated with varying rates of adverse metabolic effects, including a propensity for weight gain [ 12 – 15 ]. Proposed biological mechanisms leading to weight gain in patients treated with antipsychotics include changes in leptin [ 16 ] and adiponectin [ 17 ]. Among the second-generation antipsychotic (SGA) medications with extensive historical data, clozapine, olanzapine, quetiapine, and risperidone are associated with medium and high risk for weight gain, while aripiprazole and ziprasidone have a lower risk [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records

et al. 2017

View full text Add to dashboard Cite

BackgroundSevere and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk of weight gain has been established in short and longer-term clinical trial settings, information about lurasidone’s association with weight gain in usual clinical care is limited. This analysis of usual clinical care evaluated weight changes associated with lurasidone treatment in patients with schizophrenia or bipolar disorder.MethodsA retrospective, longitudinal analysis was conducted using de-identified electronic health records from the Humedica database for patients who initiated lurasidone monotherapy between February 2011 and November 2013. Weight data were analyzed using longitudinal mixed-effects models to estimate the impact of lurasidone on patient weight trajectories over time. Patients’ weight data (kg) were tracked for 12-months prior to and up to 12-months following lurasidone initiation. Stratified analyses were conducted based on prior use of second-generation antipsychotics with medium/high risk (clozapine, olanzapine, quetiapine, or risperidone) versus low risk (aripiprazole, ziprasidone, first-generation antipsychotics, or no prior antipsychotics) for weight gain.ResultsAmong the 439 included patients, the mean age was 42.2 years, and 69.7% were female. The average duration of lurasidone treatment across all patients was 55.2 days and follow-up duration after the index date was 225.1 days. The estimated impact of lurasidone on weight was − 0.77 kg at the end of the 1-year follow-up. Patients who had received a prior second-generation antipsychotic with medium/high risk for weight gain were estimated to lose an average of 1.68 kg at the end of the 1-year follow-up.ConclusionsLurasidone was associated with a reduction in weight at 1 year following its initiation in patients with schizophrenia or bipolar disorder. Stratified analyses indicated that weight reduction was more pronounced among patients who had received second-generation antipsychotics associated with a higher risk of weight gain prior to lurasidone treatment. These findings are consistent with the results of prior short- and long-term prospective studies and suggest that lurasidone is associated with low risk for weight gain in patients with schizophrenia or bipolar disorder.Electronic supplementary materialThe online version of this article (doi:10.1186/s12991-017-0159-x) contains supplementary material, which is available to authorized users.

show abstract

“…However, they cause troublesome metabolic side-effects such as SGA-jnduced metabolic abnormalities, increased leptin [3], and decreased adiponectin levels [4], weight gain, dyslipidemia, insulin resistance, and type II diabetes mellitus, which could further lead to the risk of cardiovascular disease and premature death [5,6,7,8]. …”

Section: Introductionmentioning

confidence: 99%

Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPKα–SREBP Pathway in 3T3-L1 Cells

Zhao

Feng

et al. 2016

IJMS

View full text Add to dashboard Cite

The aim of this study was to investigate the mechanisms underlying the inhibitory effects of berberine (BBR) on olanzapine (OLZ)-induced adipogenesis in a well-replicated 3T3-L1 cell model. Oil-Red-O (ORO) staining showed that BBR significantly decreased OLZ-induced adipogenesis. Co-treatment with OLZ and BBR decreased the accumulation of triglyceride (TG) and total cholesterol (TC) by 55.58% ± 3.65% and 49.84% ± 8.31%, respectively, in 3T3-L1 adipocytes accompanied by reduced expression of Sterol regulatory element binding proteins 1 (SREBP1), fatty acid synthase (FAS), peroxisome proliferator activated receptor-γ (PPARγ), SREBP2, low-density lipoprotein receptor (LDLR), and hydroxymethylglutaryl-coenzyme A reductase (HMGR) genes compared with OLZ alone. Consistently, the co-treatment downregulated protein levels of SREBP1, SREBP2, and LDLR by 57.71% ± 9.42%, 73.05% ± 11.82%, and 59.46% ± 9.91%, respectively. In addition, co-treatment reversed the phosphorylation level of AMP-activated protein kinase-α (AMPKα), which was reduced by OLZ, determined via the ratio of pAMPKα:AMPKα (94.1%) compared with OLZ alone. The results showed that BBR may prevent lipid metabolism disorders caused by OLZ by reversing the degree of SREBP pathway upregulated and the phosphorylation of AMPKα downregulated. Collectively, these results indicated that BBR could be used as a potential adjuvant to prevent dyslipidemia and obesity caused by the use of second-generation antipsychotic medication.

show abstract

Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis

Cited by 51 publications

References 55 publications

Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study

Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records

Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPKα–SREBP Pathway in 3T3-L1 Cells

Contact Info

Product

Resources

About